Shattuck Labs, Inc. Common Stock STTK

$5.33 -2.91% at last close
Market Cap$550.99 million
P/E Ratio—
Div Yield—
Volume1.20M
52-Week Range $1.68$8.33

Analyst Ratings

Consensus
Buy — 10 Buy · 0 Hold · 0 Sell (10 analysts)
Avg. Price Target
$15.67 (+193.9% upside)

Full STTK forecast & analyst actions →

Key Stats

Today's Range
$5.19 – $5.52
50-Day Range
$5.19 – $8.15
52-Week Range
$1.68 – $8.33
Volume
1.20 million shs
Average Volume
1.44 million shs
Market Cap
$550.99 million
P/E Ratio
—
Dividend Yield
—

Short Interest

Short Interest
0.64%
Days to Cover
1.29

About Shattuck Labs, Inc. Common Stock

Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.

Sector
PHARMACEUTICAL PREPARATIONS
Employees
40
Exchange
XNAS
Listed
2020-10-09

Related Stocks

Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.